Open AccessSubchronic Toxicity of Ivermectin and Butaphosphan in Layer Chickens
Author(s) -
E. N. Indyuhova,
М. В. Арисов,
В. Н. Максимов,
Т. В. Азарнова
Publication year - 2022
Publication title -
journal of world's poultry research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.189
H-Index - 6
ISSN - 2322-455X
DOI - 10.36380/jwpr.2022.5
Subject(s) - toxicity , lactate dehydrogenase , drug , alanine aminotransferase , medicine , therapeutic index , pharmacology , ivermectin , hemoglobin , liter , therapeutic effect , embryonated , zoology , biology , physiology , veterinary medicine , immunology , biochemistry , enzyme , inoculation
The development of new veterinary drugs to treat and prevent poultry parasitic infections, as well as the study of their safety is a hot topic for modern parasitology. The purpose of this research was to study the subchronic toxicity of the ivermectin and butaphosphan-based drugs at a therapeutic and threefold therapeutic dose during a seven-day oral administration to the Hisex White chickens. The provisional name of the drug is Iverbutan. The chickens from the first experimental group were given the drug at a threefold therapeutic dose of 3 mL of the drug per one liter of drinking water. The chickens from the second experimental group were given the drug at a therapeutic dose of 1 mL of Iverbutan per one liter of drinking water. The chickens from the control group received water without the drug. The chickens were weighed, and then the body temperature and blood samples from the axillary vein were measured on days 1, 8, and 17 of the experiment before the morning feeding. On day 8 of the study, the chickens from the first experimental group showed a 7.4% decrease in body weight and increase in body temperature by 0.8%, an increase in alanine aminotransferase activity by 2.1 times, aspartate aminotransferase activity by 1.6 times, and bile acids by 1.4 times. Moreover, there was a 4.6% decrease in glucose concentration, a 3.5% increase in lactate dehydrogenase activity, a 7.3% decrease in triglycerides, as well as a decrease in hemoglobin by 3.2% and erythrocytes by 10.6% in the first experimental group, compared to the control group. On day 17 of the experiment, the above blood parameters in the chickens from the first experimental group did not significantly differ from the control group, indicating the reversibility of the hepatotoxic effect. In this regard, a three-fold therapeutic dose can be considered a threshold. The chickens from the second experimental group showed no changes in their physiological status as compared to the control. Thus, the study results confirm the safety of the drug in the recommended dosage regimen.